**DREW KERN, MD, MS**
drew.kern@cuanschutz.edu

**Curriculum Vitae**

Academic Address
Academic Office 1
12631 East 17th Avenue, MS-B185
Aurora, CO 80045
phone: 303-724-9542
fax: 303-724-2212

Clinic Address
Anschutz Outpatient Pavilion
1635 Aurora Court, MS-F727
Aurora, CO 80045
phone: 720-848-2080
fax: 720-848-2106

**EDUCATION**

| | |
|---|---|
| 1999 | B.A. in Kinesiology (Cum Laude), University of Colorado, Boulder, CO |
| 2001 | M.S. in Kinesiology with an emphasis in Neuroscience, University of Colorado, Boulder, CO |
| 2004 | Summer Medical Student Fellow, Mentored by Felix Eckenstein, Ph.D., University of Vermont College of Medicine, Burlington, VT |
| 2006 | Translational Research Fellowship, Mentored by John Sladek, Jr., University of Colorado, Denver, CO |
| 2009 | M.D., University of Vermont, Burlington, VT |
| 2009-2010 | Internal Medicine Internship, University of Colorado, Denver, CO |
| 2010-2013 | Neurology Residency, University of Colorado, Denver, CO |
| 2013-2015 | Movement Disorders Fellowship, Mentored by Anthony Lang, MD and Alfonso Fasano, MD, PhD. University of Toronto, Toronto, ON |
| 2016 | NINDS Clinical Trials Methodology Course, National Institute of Neurological Disorders and Stroke |

**ACADEMIC APPOINTMENTS**

| | |
|---|---|
| 1999 | Research Assistant, Neural Control of Movement Laboratory, University if Colorado, Boulder, CO |
| 2000-2001 | Teaching Assistant, Biomechanics, University of Colorado, Boulder, CO |
| 2001 | Lead Teaching Assistant, Sensory Motor Neuroscience, University of Colorado, Boulder, CO |
| 2015-2021 | Assistant Professor of Neurology, University of Colorado School of Medicine |
| 2018-2021 | Adjunct Assistant Professor of Department of Neurosurgery, University of Colorado School of Medicine |
| 2021-present | Associate Professor of Department of Neurology, University of Colorado School of Medicine |
| 2021-present | Adjunct Associate Professor of Department of Neurosurgery, University of Colorado School of Medicine |

**HOSPITAL and PROFESSIONAL POSITIONS**

| | |
|---|---|
| 1997 | Intern, Cardiac Catherization Laboratory, University of California, Los Angeles, Santa Monica, CA |
| 2001-2002 | Medical Assistant, Provider: Joseph Craig, MD, Rocky Mountain Youth Medical Providers, PC (non-profit pediatric clinic), Denver, CO |
| 2002-2003 | Research Associate, Director: Rajeev Kumar, MD, "Movement disorder studies: Long-term outcomes of STN DBS," Colorado Neurological Institute, Englewood, CO |
| 2011-2013 | Resident Education Director, University of Colorado |
| 2012-2013 | Chief Neurology Resident, University of Colorado |
| 2016-2019 | Movement Disorders Resident Block Director |
| 2017-2021 | Assistant Director Outpatient Neurology Clinics, University of Colorado Hospital and University of Colorado SOM, Department of Neurology |
| 2017-2021 | Co-Director, Colorado Neurological Society |
| 2021-2022 | Interim Movement Disorders Section Head, Department of Neurology, University of Colorado SOM |
| 2019-present | Co-Director, Deep Brain Stimulation Program, Departments of Neurosurgery and Neurology, University of Colorado School of Medicine |

**HONORS, SPECIAL REGOGNITIONS, and AWARDS**

| | |
|---|---|
| 1996-1998 | Alpha Epsilon Delta (pre-honors health society), University of Colorado, Boulder, CO |
| 1996-1999 | General Honors Program (pre-requirement of 3.3 GPA), University of Colorado, Boulder, CO |
| 2000 | Travel Grant Award, University of Colorado, Boulder, CO |
| 2004 | Medical Student Summer Research Fellowship, University of Vermont College of Medicine, Burlington, VT |
| 2007 | ASNTR Student Travel Grant Award, American Society for Neural Transplant and Repair |
| 2008 | AFAR Research Grant Award, American Foundation for Aging Research |
| 2009 | The Herbert Martin Sr. Award for Excellence in Neurology, University of Vermont College of Medicine |
| 2011 | The Arnold P. Gold Foundation Award for Humanism and Excellence in Teaching, University of Colorado, Aurora, CO |
| 2013 | Resident Research Award, University of Colorado, Department of Neurology |
| 2013-2014 | Clinical Movement Disorders Fellowship Award, Parkinson Society of Canada |
| 2014 | International Parkinson and Movement Disorder Society Travel Award, University of Toronto |
| 2016 | Student Loan Repayment Program, National Institutes of Health Loan Repayment Program (funding $70,000) |
| 2017-2018 | Faculty Development Award, Adamas Pharmaceuticals, Inc. (funded $ 9000) |
| 2019 | Parkinson Study Group Visiting Mentor Program Award (funded $ 7450) |
| 2022 | Fellow of the American Academy of Neurology |
| 2023 | Delphi Study Participant (expert DBS panel) |

**MEMBERSHIP IN PROFESSIONAL ORGANIZATIONS**

2003-present American Academy of Neurology
2003-2006 Student Interest Group of Neurology
2006-2008 Front Range Neuroscience Group
2007-2008 Society for Neurosciences
2007-2008 American Association for the Advancement of Science
2015-present American Academy of Neurology
2013-present International Parkinson and Movement Disorders Society
2015-present Parkinson Study Group
2015-present Colorado Neurological Society
2016-present American Neurological Association
2022-present Deep Brain Stimulation Society

**MAJOR COMMITTEE and SERVICE RESPONSIBILITIES**

2007 Judge of Denver Metro High School Students' Poster Presentations, Denver Metro Regional Science and Engineering Fair
2013-2015 Biomarkers in Parkinson's Disease, Michael J. Fox Foundation
2015-present Functional Neurosurgical Working Group, Parkinson Study Group
2016-present Data Safety Monitoring Board, Colorado Clinical and Translational Sciences Institute (CCTSI)
2016-present AbbVie Pharmaceuticals – Marketing and Medical Board
2018-2019 Denali Therapeutics – Medical Board
2019-2020 Quality Case Review Committee – University of Colorado
2018-present Medtronic – Medical Board
2018-present Boston Scientific – Medical Advisor

**LICENSURE and BOARD CERTIFICATION**

1998 Emergency Medical Technician Certification
2000 National Institute of Health Research Certification
2009-2013 State of Colorado Training License
2013 Board-Certified in Neurology, American Board of Psychiatry and Neurology
2013-2015 Postgraduate License, College of Physicians and Surgeons in Ontario
2013-present State of Colorado Medical License
2022-present State of Wyoming Medical License
2022-present State of New Mexico Medical License

**REVIEW and REFEREE WORK**

2015 Movement Disorders Journal
2016 The Clinical Neuropsychologist
2016, 2023 Parkinsonism and Related Disorders
2016 The Journal of Neuropsychiatry and Clinical Neurosciences.
2016 Knoebel Institute for Health Aging, University of Denver, Denver, CO

| | |
|---|---|
| 2015-present | Movement Disorders Center Pilot Grant, University of Colorado, Aurora, CO |
| 2017 | Parkinsonism Biomarker Review Committee – ZNS1 SRB-T (29) National Institute of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS) |
| 2019 | Neurological Foundation of New Zealand |
| 2020 | Brain Sciences |
| 2020 & 2021 | American Academy of Neurology Annual Meeting of 2020, Abstract Review |
| 2021 | Neurology Clinical Practice |
| 2022& 2023 | Frontiers in Neurology, section Experimental Therapeutics |
| 2022 | Brain Communications |
| 2022 | Sensors |
| 2022 | Journal of the Neurological Sciences |
| 2022 | Virginia Commonwealth University, Parkinson's & Movement Disorders Center, pilot grant reviewer |
| 2023 | Neurotherapeutics |

**INVITED EXTRAMURAL LECTURES, PRESENTATIONS, and VISITING PROFESSORSHIPS**

**Oral Presentations/Lectures - Institutional**

Neuroscience Conference at Swedish Medical Center *Sustained long-term benefit and adverse effects of bilateral subthalamic nucleus (STN) deep brain stimulation (DBS) in Parkinson's disease (PD).* December 11, 2002 Englewood, CO

University of Colorado Denver, Grand Rounds *Alpha-synuclein in skin: the need for a methodological approach*. May 22, 2013 Aurora, CO

University of Toronto, Movement Disorders Journal Club *A pilot study of focused ultrasound thalamotomy for essential tremor.* August 21, 2013 Toronto, ON

University of Toronto, Movement Disorders Video Rounds *NBIAs.* October 7, 2013 Toronto, ON

University of Toronto, Movement Disorders Journal Club *A two-year randomized controlled trial of progressive resistance exercise for Parkinson's disease.* October 16, 2013 Toronto, ON

University of Toronto, Movement Disorders Journal Club *Alpha-synuclein in cutaneous autonomic nerves.* November 13, 2013 Toronto, ON

University of Toronto, Movement Disorders Video Rounds *AOAs.* December 9, 2013 Toronto, ON

University of Toronto, Movement Disorders Video Rounds *DBS cases.* December 9, 2014 Toronto, ON

University of Toronto, Movement Disorders Journal Club *Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial.* January 29, 2014 Toronto, ON

University of Toronto, Movement Disorders Journal Club *Comparison of pregabalin with pramipexole for restless legs syndrome.* February 19, 2014 Toronto, ON

University of Toronto, Movement Disorders Video Rounds *MSA.* February 24, 2014 Toronto, ON

University of Toronto, Movement Disorders Journal Club *Randomized trial of salfinamide add-on to levodopa in Parkinson's disease with motor fluctuations.* March 26, 2014 Toronto, ON

University of Toronto, Movement Disorders Video Rounds *PLMT.* May 18, 2014 Toronto, ON

University of Toronto, Movement Disorders Journal Club *Peripheral hypoxia in restless legs syndrome (Willis-Ekbom disease).* June 4, 2014 Toronto, ON

University of Toronto, Movement Disorders Video Rounds *Tics.* June 30, 2014 Toronto, ON

University of Toronto, Movement Disorders Journal Club *Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson's disease.* August 6, 2014 Toronto, ON

University of Toronto, Movement Disorders Journal Club *Droxidopa for neurogenic orthostatic hypotension.* August 20, 2014 Toronto, ON

University of Toronto, Movement Disorders Journal Club *The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa.* September 24, 2014 Toronto, ON

University of Toronto, Movement Disorders Video Rounds *Tremor and DBS.* October 6, 2014 Toronto, ON

University of Toronto, Movement Disorders Journal Club *Deferiprone in Friedreich ataxia: a 6-month randomized controlled trial.* November 19, 2014 Toronto, ON

University of Toronto, Movement Disorders Journal Club *Should genetic testing for SCAs be included in the diagnostic workup for MSA?.* December 17, 2014 Toronto, ON

University of Toronto, Movement Disorders Journal Club *Mendelian randomization of serum urate and Parkinson disease progression.* January 7, 2015 Toronto, ON

University of Toronto, Movement Disorders Video Rounds *Myoclonus.* February 9, 2015 Toronto, ON

University of Toronto, Movement Disorders Journal Club *Parkinson risk in idiopathic REM sleep behavior disorder.* March 18, 2015 Toronto, ON

University of Toronto, Movement Disorders Journal Club *Rytary.* April 29, 2015 Toronto, ON

University of Toronto, Movement Disorders Journal Club *Causes of withdrawal of duodenal levodopa infusion in advanced Parkinson disease.* May 27, 2015 Toronto, ON

University of Toronto, Movement Disorders Video Rounds *Chorea.* June 1, 2015 Toronto, ON

Department of Neurology Grand Rounds *Ironing out neurodegeneration with brain iron accumulation*. November 4, 2015, Aurora, CO

Neurosurgery Morning Research Rounds *Deep brain stimulation (DBS) of the zona incerta (Zi): stereotactic targeting an assessment of clinical outcomes compared with traditional targets.* March 22, 2016 Aurora, CO

Behavioral Neurology and Neuropsychiatry *Cognition in deep brain stimulation (DBS) for movement disorders: evaluation and outcomes.* November 1, 2016 Aurora, CO

Neurosurgery Morning Research Rounds *Deep brain stimulation (DBS) of the rostral zona incerta (rZi) for treatment of Parkinson's disease: stereotactic targeting and clinical efficacy.* November 22, 2016 Aurora, CO

University of Colorado Denver, Neurorehabilitation Rounds, *Functional movement disorders.* September 27, 2017 Aurora, CO

Department of Neurology Grand Rounds *Many roads lead to Parkinson's disease: understanding the causes and progression.* December 6, 2017Aurora, CO
Department of Neurology Grand Rounds *Practice transformation.* February 21, 2018 Aurora, CO
Department of Neurology Grand Rounds *Surgical targets less talked about in deep brain stimulation for movement disorders.* August 29, 2018 Aurora, CO
Department of Neurology Grand Rounds *Current and future research in deep brain stimulation at the University of Colorado.* August 29, 2020 Aurora, CO
Department of Neurology Grand Rounds *MRI Guided Focused Ultrasound at the University of Colorado: Review, Unknown, and Experience.* February 16, 2022 Aurora, CO

**Oral Presentations/Lectures – National**

Northern New England Neurological Society *Not all that shakes is narcolepsy.* October 29, 2005 Portsmouth, NH
Michael J. Fox Foundation *Alpha-synuclein in skin: the need for a methodological approach*. June 6, 2013 New York, NY
International Parkinson and Movement Disorders Society *Video Challenge* June 17, 2015 San Diego, CA
Parkinson Study Group Surgical Study Group *Interleaved stimulation: where are we and where should we go?* September 17, 2016 Portland OR
John R. Sladek Jr. Symposium *Application of lessons learned during my research fellowship: Skin as a potential biomarker in Parkinson's disease*. October 22, 2015 Aurora, CO
Neuroscience Summit *Movement disorders and surgical interventions*. September 11, 2018 Aurora, CO
Neurosurgery in the Rockies Conference. *Deep Brain Stimulation for Movement Disorders: Simplified to Complex Programming* February 24, 2020. Beaver Creek, CO
Neurosurgery in the Rockies Conference. *MRI Guided Focused Ultrasound – Gaps*. February 28, 2022. Beaver Creek, CO
ASSFN Hands-On Course. *DBS Programming*. November 13, 2022. Aurora, CO

**Oral Presentations/Lectures – International**

University of Calgary Movement Disorder Rounds. *Deep brain stimulation: Current and future directions*. June 18, 2020 Calgary, AB

**Poster Presentations**

American College of Sports Medicine – June 2, 2000
*Chronic surface EMG during normal daily use*; Indianapolis, IN
American Academy of Neurology – April 1, 2003
*Effective subthalamic nucleus (STN) deep brain stimulation (DBS) in levodopa-unresponsive parkinsonism;* Honolulu, HI
American Academy of Neurology **–** April 1, 2003
*Sustained long-term benefit and adverse effects of bilateral subthalamic nucleus (STN) deep brain stimulation (DBS) in Parkinson's disease (PD);* Honolulu, HI
Society for Neuroscience – October 14, 2006

*Effects of neural stem cell transplantation on total tau in an aged animal model of Down syndrome, Ts65Dn;* Atlanta, GA

Front Range Neuroscience Group – November 13, 2006

*Effects of neural stem cell transplantation on total tau in an aged animal model of Down syndrome, Ts65Dn;* Fort Collins, CO

American Society for Neural Therapy and Repair – May 3, 2007

*Short-term neural stem cell treatment in the Ts65Dn mouse model of Down syndrome did not significantly affect total tau in the hippocampus and olfactory bulbs;* Clearwater, FL

Society for Neuroscience – November 4, 2007

*Biocompatibility of poly(ethylene) glycol-based hydrogel in healthy brain tissue;* San Diego, CA

American Foundation for Aging Research – November 8, 2008

*Tau analysis within the Ts65Dn mouse, a model of Down syndrome;* Raleigh, NC

University of Toronto Research Retreat - January 23, 2014

*Methodological approaches for evaluating alpha-synuclein in skin as a potential biomarker in Parkinson's disease;* Toronto, ON

International Congress of Parkinson's Disease and Movement Disorders – June 9, 2014

*Methodological approaches for evaluating alpha-synuclein in skin as a potential biomarker in Parkinson's disease;* Stockholm, Sweden

International Congress of Parkinson's Disease and Movement Disorders – October 6, 2018

*Optimized Imaging at 3.0 T of the Rostral Zona Incerta (rZI) for Deep Brain Stimulation (DBS) in Parkinson's Disease (PD);* Hong Kong, China

American Academy of Neurology *Enhancing Care Teams with Medical Assistants: A Novel Clinic Model* May 5, 2019 Philadelphia, PA

International Congress of Parkinson's Disease and Movement Disorders – September 25, 2019

*Rapid improvement in dystonia after pallidal deep brain stimulation in a patient with myoclonus-dystonia syndrome: A case report;* Nice, France

International Congress of Parkinson's Disease and Movement Disorders – September 25, 2019

*Correlation of local field potentials (LFPs) to electromyography (EMG) of the rostral zona incerta (rZI) and subthalamic nucleus (STN) in Parkinson's Disease (PD);* Nice, France

International Congress of Parkinson's Disease and Movement Disorders – September 24, 2019

*Characteristics of patients with essential tremor evaluated for deep brain stimulation surgery at a tertiary center;* Nice, France

American Academy of Neurology Annual Meeting - Virtual 2020

*Neuro-anatomical volumetric changes in deep brain stimulation of Parkinson's disease patients*

International Congress of Parkinson's Disease and Movement Disorders – September 17, 2022

*Pilot study to investigate the use of in-clinic sensing to identify optimal stimulation parameters for deep brain stimulation therapy in Parkinson's disease*

Advanced Therapeutics in Movement & Related Disorders (ATMRD) Congress – June 9, 2023
*Safety of Foslevodopa/Foscarbidopa During Optimization and Maintenance Treatment: Post Hoc Analysis of a Phase 3 Trial*
North American Neuromodulation Society Annual Meeting – January 18-21, 2024
*Towards an objective, standardized beta frequency peak detection algorithm to inform deep brain stimulation programming in Parkinson's disease*

**TEACHING RECORD**

Movement Disorders Resident Block Director
2017- 2019
Responsible for the core resident education on movement disorders

Medical Student and resident rotations in Movement disorders Clinics
2015-present
Bedside teaching of movement disorders including examination, diagnosis, work-up and treatment at UCHealth and Denver Health.

American Society for Stereotactic and Functional Neurosurgery (ASSFN)
2018, 2019, 2022
Hands-on teaching to residents and fellows of neurology and neurosurgery in stereotactic and functional neurology in deep brain stimulation programming

**Mentoring Record**

<u>Movement Disorder Neurology Fellows</u>

- Kristin King, MD (2017-2018)
- Kristin Mitrovich, MD (2017-2018)
- Trevor Hawkins, MD (2016-2018)
- Christopher Groth, MD (2016-2018)
- Lisa Deuel, MD (2018-2019)
- Jeanne Feuerstein (2018-2019)
- Caroline Goldin (2019-2020)
- Theresa Lee (2019-present)
- Alexander Baumgartner (2020-2022)
- Michael Korsmo (2020-2022)
- Antonia Pusso (2021-2023)
- Heather Heiser (2021-2023)
- Matthew Woodward (2022-present)
- Brooke Heffernan (2022-present)
- Stereotactic and Functional Neurosurgery Hands-On Workshop, Annual Course. 2018, 2019, & 2022. Aurora, Colorado. Lecture and workshop on deep brain stimulation taught to nationally invited neurosurgery fellows and residents throughout North America.

<u>Residents</u>

- Ian McGuinness, MD (2018-2019). Review goals of education and career development

- John "Kyle" Jenkins, MD (2019-present). Review goals of education and career development

Medical Students

- Mashal Talat (2018), visiting international student, supervisor for extended observership
- Yaswanth Chintaluru (2020-present), medical student at University of Colorado pursuing a research track, co-mentor

Graduate Students

- Nathan Davis, candidate for Master's of Modern Human Anatomy (2018-2019), advisor for capstone project
- Gary Cahill, candidate for Master's of Modern Human Anatomy (2018-2019), advisor for capstone project

**COMMUNITY SERVICE**

Volunteer in Classroom with 3rd Grade Developmental Delayed Children, Bal Swan Children's Center, 1998 Broomfield, CO

Aurora Central High School. *Nervous System*. November 9, 2017 Aurora CO

Patient Education

E3 Conference Parkinson Association of the Rockies. *Sleep and Fatigue in Parkinson's Disease.* October 9, 2015 Denver CO

Parkinson Association of the Rockies. *Fatigue and sleep disorders in Parkinson's disease and resources at the University of Colorado, Movement Disorders Center.* May 14, 2016 Grand Junction, CO

Bionic Brigade DBS Support Group. *DBS in Movement Disorders*. November 11, 2016. Englewood CO

Parkinson Support Group. *Carbidopa Levodopa Enteral Suspension*. April 7, 2017 Aurora CO

Parkinson Support Group. *Sleep and Fatigue*. June 16, 2017 Westminster CO

Colorado Neurological Institute. *Pathogenesis of Parkinson Disease*. November 11, 2017 Englewood CO

Boulder Support Group. *Parkinson Disease*. October 23, 2018 Boulder CO

Tri Lakes Support Group*. Advanced Parkinson's Disease Treatments.* June 16, 2018 Englewood CO

Parkinson Association of the Rockies *PD 101: Medications* May 15, 2019

Longmont Parkinson Disease Support Group *Advanced Treatments for Parkinson's Disease* June 12, 2019

Davis Phinney Foundation Webinar *Parkinson's Research & Clinical Trials* October 16, 2019

Parkinson Association of the Rockies *Deep Brain Stimulation for Parkinson's Disease and Essential Tremor* May 21, 2020

Parkinson Association of the Rockies *Advanced PD Treatments* June 11, 2020

Parkinson and Movement Disorders Alliance *Collaboration of Neuro-palliative care and Advanced Treatments in Movement Disorders* July 29, 2020

Movement Disorders Foundation 2nd Annual Seminar. *Treatment of complex motor problems in Parkinson's disease* August 29, 2020

INSIGHT Into Parkinson's 2023. *What is Advanced PD?* April 2023.

INSIGHTEC. *From Dependent to Independent: Treatment Options for Essential Tremor* July 23, 2023, September 24, 2023, November 12, 2023, and January 14, 2023.

Graduate Education Lectures

Sensory Motor Neuroscience Course *Locomotion.* University of Colorado Boulder. April, 4, 2001 Boulder, CO

Sensory Motor Neuroscience Course *Basal ganglia disorders.* University of Colorado Boulder. April 27, 2001 Boulder, CO

Neurology Resident Education *Phenomenology of movement disorders.* University of Colorado School of Medicine. August 19, 2015 Aurora, CO

Neurology Resident Education *Movement disorders emergencies.* University of Colorado School of Medicine. July 27, 2017 Aurora, CO

Neurology Resident Education *Phenomenology and anatomy of movement disorders.* University of Colorado School of Medicine. October 11, 2017 Aurora, CO

Neurology Resident Education *Functional movement disorders.* University of Colorado School of Medicine. October 11, 2017 Aurora, CO

Neurology Resident Education. *Phenomenology.* University of Colorado School of Medicine. December 5, 2018 Aurora, CO

Neurology Resident Education. *Functional Movement Disorders.* University of Colorado School of Medicine. February 27, 2019 Aurora, CO

Neuropsychology Fellowship Lecture Series, Department of Neurosurgery. *Approach to functional movement disorders*. University of Colorado School of Medicine. March 13, 2018 Aurora, CO

Neuropsychology Seminar. *Diagnosis of Parkinson's Disease and other Movement Disorders.* University of Colorado School of Medicine. March 13, 2019 Aurora, CO

Neurology Resident Education. *Advanced Parkinson Disease.* University of Colorado School of Medicine. October 23, 2019 Aurora, CO

Neurology Resident Education. *Botulinum Toxin and Deep Brain Stimulation Introduction and Workshop.* University of Colorado School of Medicine. October 30, 2019 Aurora, CO

Clinician Education Lectures

Colorado Neurological Society *Droxidopa for the treatment of neurogenic orthostatic hypotension*. September 21, 2015 Denver, CO

Colorado Neurological Society *When to initiate levodopa,* February 17, 2016 Denver, CO

University of Colorado Denver, Movement Disorders Lecture *Filling the gaps: treatments for advanced Parkinson's disease.* June 16, 2016 Aurora, CO

University of Colorado Denver, Resident Education *Movement disorders emergencies.* July 14, 2016 Aurora, CO

University of Colorado Denver Resident Education *Phenomenology and anatomy of movement disorders.* September 28, 2016 Aurora, CO

Good Samaritan. *Advanced Treatments in Parkinson Disease*. July 20, 2017 Lafayette CO

Boulder General Clinicians. *DBS Therapy*. August 25, 2017 Boulder CO
UC Health Neurology Clinics and Banner Health. *Advanced Treatments*. March 21, 2018 Fort Collins CO
Miramont Family Practice. *Tremor: Diagnosis and treatment*. April 5, 2018 Fort Collins CO
Colorado Springs Educational Dinner (Colorado Springs Neurology Associates, UCHealth Neurology, and DaVita Internal and Family Medicine) *Advanced Treatments for Movement Disorders* May 22, 2019 Colorado Springs, CO
Colorado Neurological Society. *Deep Brain Stimulation Interesting Cases* March 9, 2020. Denver, CO
PD Foundation COE. *Advanced Therapies in Parkinson's Disease* March 1, 2021; March 8, 2021; April 26, 2021; May 6, 2021; May 24, 2021; June 14, 2021. Denver, CO

Media
AARP Webinar and Parkinson Association of the Rockies. *Parkinson Disease and Non-motor symptoms: Sleep Disorders and Fatigue.* November 4, 2016 Denver CO
No Copay Radio Interview. *Parkinson Disease*. February 15, 2018 Denver CO

**GRANT SUPPORT**

**Current Independent Investigator Studies**

LFP sensing from directional leads and associated clinical outcomes in the acute clinical setting
Funding: Medtronic
Role: Principal Investigator
Total Costs (Direct and Indirect): $136,919

Predicting the optimal therapeutic contact of a deep brain stimulation electrode in Parkinson's disease based upon measurement of beta activity
Funding: Medtronic
Role: Principal Investigator
Total Costs (Direct and Indirect): $22,720

Narrowing the knowledge gap between primary care providers (PCPs) and movement disorders neurologists in the treatment of advanced PD
Funding: Parkinson's Foundation Center of Excellence Core Grant
Role: Principal Investigator
Total Costs (Direct and Indirect): $25,000 Directs (Indirects not allowed)

Improving efficiency of initial DBS programming for electrodes with multiple independent constant current
Funding: Boston Scientific
Role: Principal Investigator
Total Costs (Direct and Indirect): $87,907.00 Directs $112,520.96 w/ Indirects

Sex disparities in patients with essential tremor
Funding: University of Colorado, Movement Disorders Center Grant

Role: Co-Investigator, Co-mentor

Evaluating the impact of adding 3D printed brains to pre-surgical patient education meetings
Funding: Investigator research account (John Thompson) and Gerhard Family Gift
Role: Co-Investigator

Patient preference in deep brain stimulation products
Funding: Investigator research account (Drew Kern)
Role: Co-Investigator, Co-mentor

**Current Industry and Foundation Funded Studies**

A Multi-Center, Controlled Study to Evaluate Use of CereGate Therapy to Reduce Freezing of Gait in Participants Diagnosed with Parkinson's Disease
Funding: Ceregate Inc.
Role: Principal Investigator
Total Costs (Direct and Indirect): $10,209 Directs $12,761 w/ Indirects

Registry of deep Brain stimulation with the VERCISE™ System: Vercise™ DBS registry
Sponsor: Boston Scientific
Role: Site Principal Investigator
Total Costs (Direct and Indirect): $168,044.92 Directs $215,097.50 w/ Indirects (estimating 25 patients)

Parkinson's disease: safety and tolerability of 24-hour daily exposure to ABBV-951 by continuous subcutaneous infusion (M15-741)
Sponsor: AbbVie, Inc
Role: Site Principal Investigator
Total Costs (Direct and Indirect): $270,470.00 Directs $346,201.60 w/ Indirects

Advanced Parkinson's disease: double-blind, double-dummy, active-controlled, efficacy and safety of ABBV-951 versus oral carbidopa-levodopa (M15-736)
Sponsor: AbbVie, Inc
Role: Site Principal Investigator
Total Costs (Direct and Indirect): $274,980 Directs $351,974.40 w/ Indirects

Parkinson's Disease: An extension of Study M15-741 evaluating the safety and tolerability of ABBV-951 in subjects with Parkinson's disease
Sponsor: AbbVie, Inc
Role: Site Principal Investigator
Total Costs (Direct and Indirect): $378,153.79 Directs $525,213.60 w/ Indirects

Parkinson's Disease: A comparative study of levodopa and carbidopa bioavailability following foslevodopa/foscarbidopa infusion at different subcutaneous sites in Parkinson's disease patients (M20-339)

Sponsor: AbbVie, Inc
Role: Site Principal Investigator
Total Costs (Direct and Indirect): $428,692.72 Directs $595,406.56 w/ Indirects

Advanced Parkinson's disease: An open-label extension of studies M15-736 and M20-339 evaluating the safety and tolerability of ABBV-951 (M20-098)
Sponsor: AbbVie, Inc
Role: Site Principal Investigator
Total Costs (Direct and Indirect): $536,081.65 Directs $744,557.84 w/ Indirects

**Completed Independent Investigator Studies**

Deep brain stimulation (DBS) of the rostral zona incerta (rZI) for Parkinson's disease (PD)
Funding: Department of Neurology Intradepartmental Grant
Role: Principal Investigator
Total Costs (Direct and Indirect): $40,000 Directs (Indirects not allowed)

Alpha-synuclein deposition in skin of patients with Parkinson's disease, multiple systems atrophy, and progressive supranuclear palsy
Funding: Skin Disease Research Center, University of Colorado Grant
Role: Principal Investigator

Cutaneous alpha-synuclein staining as a diagnostic marker for Parkinson's disease and related disorders.
University Health Network, REB #12-0447-AE
Role: Co-Investigator

Synuclein staining in the rectosigmoid mucosa as a diagnostic biomarker for Parkinson's disease
University Health Network, REB #12-0374-A
Role: Co-Investigator

**Completed Industry and Foundation Funded Studies**

A randomized, placebo surgery controlled, double-blinded, multi-center, phase 2 clinical trial, evaluating the efficacy and safety of VY-AADC02 in advanced Parkinson's disease with motor fluctuations
Sponsor: Voyager Therapeutics
Role: Site Sub-Investigator

A post-market study evaluating the safety of Infinity DBS system with MR conditional labeling
Sponsor: Abbott
Role: Site Sub-Investigator

Registry for the advancement of DBS for Parkinson's disease (RAD-PD)
Sponsor: Parkinson Study Group and Michael J. Fox Foundation
Role: Site Principal Investigator

Total Costs (Direct and Indirect): $26,000 Directs $30,375 w/ Indirects (25% paid on patient care only per contract)

A phase 3, open-label study of the safety, efficacy, and tolerability of apomorphine administered by continuous subcutaneous infusion in advanced Parkinson's disease patients with unsatisfactory control on available therapy
Sponsor: USWM
Role: Site Sub-Investigator

A multicenter, international, open-label, safety study of ND0612, a solution of levodopa/carbidopa delivered via a pump system as a continuous subcutaneous infusion in subjects with advanced Parkinson's Disease
Sponsor: Neuroderm, Ltd.
Role: Site Sub-Investigator

A phase 1B, multicenter, randomized, placebo-controlled, double-blind study to determine the safety, tolerability, pharmokinetics, and pharmacodynamics of DNL201 in subjects with Parkinson's disease
Sponsor: Denali Therapeutics Inc
Role: Site Principal Investigator
Total Costs (Direct and Indirect): $300,725 Directs $384,928 w/ Indirects

A phase 3, long-term, open-label and single-arm study of MYOBLOC® in the treatment of troublesome sialorrhea in adult subjects
Sponsor: Solstice
Role: Sub-Investigator

**BIBLIOGRAPHY**

**Original full-length manuscripts (published, in press, or submitted)**

1. **Kern DS**, Semmler JG, and Enoka RM. Long-term activity in upper- and lower-limb muscles of humans. *J Appl Physiol 91*: 2224-2232, 2001.
2. **Kern DS** and Kumar R. Deep brain stimulation. *Neurologist* 13:237-252, 2007.
3. Eckenstein FP, McGovern TK, **Kern DS**, and Deignan J. Neuronal vulnerability in transgenic mice expressing an inducible dominant negative FGF receptor. *Exp Neurol* 198:338-349, 2006.
4. **Kern DS** and Kumar R. Deep brain stimulation for movement disorders. *CNI Review* 2008.
5. Bjugstad KB, Redmond Jr. DE, Lampe KJ, **Kern DS**, Sladek Jr. JR, Mahoney MJ. Biocompatibility of PEG-based hydrogels in primate brain. *Cell Transplantation* 17:409-415, 2008.

   Bjugstad KB, Lampe K, **Kern DS**, Mahoney M. Biocompatibility of poly(ethylene glycol)-based hydrogels in the brain: an analysis of the glial response across space and time. *J Biomed Mater Res A*. 2010t;95(1):79-91.

**Kern DS**, Maclean KN, Jiang H, Snyder EY, Jr JR, Bjugstad KB. Neural stem cells reduce hippocampal tau and reelin accumulation in aged Ts65Dn Down syndrome mice. *Cell Transplantation*. 2011;20(3)371-379.

Lampe K, **Kern DS**, Bjugstad KB, Mahoney M. The administration of BDNF and GDNF to the brain via PLGA microparticles patterned within a degradable PEG-based hydrogel: protein distribution and the glial response. *Journal of Biomedical Materials Research: Part A.* 2011;96(3):595-607.

**Kern DS**, Fox SH. Review of 'Elias WJ, Huss D, Voss T et al. A pilot study of focused ultrasound thalamotomy for essential tremor. N Engl J Med. 2013': *Neurodegen Dis Manage*.2013;3(6):1.

Visanji NP, Marras, C, **Kern DS**, AlDakheel A, Gao A, Liu LWC, Lang AE, Hazrati LN. Colonic mucosal alpha-synuclein lacks specificity as a biomarker for Parkinson's disease. *Neurology*. 2015 Feb 10;84(6):609-16.

**Kern DS**, Lang AE. Successful treatment of functional palatal tremor: Insights into pathogenesis and management. *Mov Disord*. 2015 May;30(6):875-6.

Picillo M, Vincos GB, **Kern DS**, Lang AE, Fasano A. Learning more from finger tapping in Parkinson's disease: up and down from dyskinesia to bradykinesia. *Mov Disord Clin Pract*. 2015 Oct 27.

Tekriwal A, **Kern DS**, Tsai J, Ince NF, Thompson J, Abosch A. REM Sleep Behavior Disorder: Prodromal and Mechanistic Insights for Parkinson's Disease. *JNNP*. 2017 May;88(5):445-451.

Visanji NP, Bhudhikanok GS, Mestre TA, Ghate T, Udupa KU, Kowgier M, Al Dakheel A, Connolly BS, Gasca-Salas C, **Kern DS**, Singerman J, Slow EJ, Socher A, Kim S, Valappil RA, Kausar F, Rogaeva E, Langston JW, Tanner CM, Schüle B, Lang AE, Goldman SM, Marras C. *Heart rate variability in LRRK2-associated Parkinson's Disease*. *Mov Disord*. 2017 Apr;32(4):610-614.

Fullard M, Thibault D, Hill A, Fox J, Bhatti D, Burack MA, Dahodwala N, Haberfeld E, **Kern DS**, Klepitskaya OS, Urrea-Mendoza E, Myers P, Nutt JG, Rafferty M, Schwalb JM, Shulman LM, Willis AW. Utilization of Rehabilitation Therapy Services in Parkinson's disease in the United States. *Neurology.* 2017 Sep 12;89(11):1162-1169.

**Kern DS**, Forbes E, Shah BB. Surgical Interventions for Parkinson's Disease. Practical Neurology. 2018 May 2018

Fullard ME, Thibault DP, Todaro V, Foster S, Katz L, Morgan R, **Kern DS**, Schwalb JM, Urrea Mendoza E, Dahodwala N, Shulman L, Willis AW. Sex disparities in health and health care utilization after Parkinson diagnosis: Rethinking PD associated disability. *Parkinsonism Relat Disord*. 2018 Mar;48:45-50.

van den Heuvel L, Lim AS, Visanji NP, Huang J, Ghate T, Mestre TA, AlDakheel A, Connolly BS, Gasca-Salas C, **Kern DS**, Jain J, Slow EJ, Pondal M, Faust-Socher A, Rogaeva E, Tomlinson G, Lang AE, Marras C. Actigraphy Detects Greater Intra-Individual Variability During Gait in Non-Manifesting LRRK2 Mutation Carriers. *J Parkinsons Dis*. 2018;8(1):131-139.

Arora S, Visanji NP, Mestre TA, Tsanas A, AlDakheel A, Connolly BS, Gasca-Salas C, **Kern DS**, Jain J, Slow EJ, Faust-Socher A, Lang AE, Little MA, Marras C. Investigating Voice as a

Biomarker for Leucine-Rich Repeat Kinase 2-Associated Parkinson's Disease. J Parkinsons Dis. 2018;8(4):503-510.

Mestre TA, Pont-Sunyer C, Kausar F, Visanji NP, Ghate T, Connolly BS, Gasca-Salas C, **Kern DS**, Jain J, Slow EJ, Faust-Socher A, Kasten M, Wadia PM, Zadikoff C, Kumar P, de Bie RM, Thomsen T, Lang AE, Schüle B, Klein C, Tolosa E, Marras C. Clustering of motor and nonmotor traits in leucine-rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study. *Mov Disord*. 2018 Jul;33(6):960-965.

**Kern DS**, Picillo M, Thompson JA, Sammartino F, di Biase L, Munhoz RP, Fasano A. Interleaving stimulation in Parkinson's disease, tremor and dystonia. *Stereo Funct Neurosurg*. 2018;96:379-391.

Deuel L, Collins AE, Maa EH, Barr JP, **Kern DS**. Dravet syndrome and parkinsonism: A case report investigating the dopaminergic system.*Neurology*. 2019 Sep 24;93(13):595-596

Tekriwal A, Afshar NM, Santiago-Moreno J, Kuijper FM, **Kern DS**, Halpern CH, Felsen G, Thompson JA. Neural Circuit and Clinical Insights from Intraoperative Recordings During Deep Brain Stimulation Surgery. *Brain Sci*. 2019 Jul 20;9(7)

Pang Y, Christenson J, Jiang F, Lei T, Rhoades R, **Kern DS**, Thompson JA, Liu C. Automatic detection and quantification of hand movements toward development of an objective assessment of tremor and bradykinesia in Parkinson's disease. *J Neurosci Methods*. 2020 Mar 1;333:108576.

**Kern DS**, Uy D, Rhoades R, Ojemann SG, Abosch A, Thompson JA. Discrete changes in brain volume after Deep Brain Stimulation in Parkinson patients. *JNNP*. 2020 Sep;91(9):928-937.

**Kern DS**, Fasano A, Thompson JA, Abosch A, Ojemann S, Munhoz RP. Constant current versus constant voltage: clinical evidence supporting the fundamental difference in the modalities. *Stereotactic and Functional Neurosurgery*. 2021 99(2);171-5.

Bally JF, Camargos ST, Santos C, **Kern DS**, Lee T, Pereira da Silva-Júnior F, Renato Puga, Cardoso F, Barbosa E, Yadav R, Ozelius L, Aguiar P, Lang AE. DYT-TUBB4A (DYT4 dystonia): New clinical and genetic observations. *Neurology*. 2021 Apr 6;96(14):e1887-e1897.

Davis RA, Winston H, Gault JM, **Kern DS**, Mikulich-Gilbertson SK, Abosch A. Deep Brain Stimulation for OCD in a Patient With Comorbidities: Epilepsy, Tics, Autism, and Major Depressive Disorder. *The Journal of Neuropsychiatry and Clinical Neurosciences.* 2021 Spring;33(2):167-171.

Thaker AA, Reddy KM, Thompson JA, Gerecht PD, Brown MS, Abosch A, Ojemann SG, **Kern DS**. Coronal Gradient Echo MRI to Visualize the Zona Incerta for Deep Brain Stimulation Targeting in Parkinson's Disease. *Stereotactic and Functional Neurosurgery*. 2021;99(5):443-450.

Baumgartner AJ, Kushida CA, Summers MO, **Kern DS***, Abosch A, Thompson JA. Basal ganglia local field potentials as a potential biomarker for sleep disturbance in Parkinson's disease. *Frontiers in Neurology*. (2021):1957. *Co-senior author.

Hirt L, **Kern DS**, Ojemann S, Grassia F, Kramer D, Thompson JA. Use of three-dimensional printed brain models during deep brain stimulation surgery consultation for patient

health literacy: a randomized controlled investigation. *World Neurosurgery*. 2022 Mar 17.

Hirt L, Thies KA, Ojemann S, Abosch A, Darwin ML, Thompson JA, **Kern DS**. Case series investigating the differences between stimulation of rostral zona incerta region in isolation or in conjunction with the subthalamic nucleus on acute clinical effects for Parkinson's disease. *Interdisciplinary Neurosurgery*. 2022 Apr 4:101553.

Fearon C, Rawal S, Olszewska D, Alcaide-Leon P, **Kern DS**, Sharma S, Jaiswal SK, Murthy JM, Ha AD, Schwartz RS, Fung VS. Neuroimaging Pearls from the MDS Congress Video Challenge. Part 2: Acquired Disorders. *Movement Disorders Clinical Practice*. 2022 Feb 3;9(3):311-325.

**Kern DS**, Korsmo M, Baumgartner AJ, Kramer D, Ojemann S, Case M, Holt-Becker AB, Raike R, Thompson JA. Methylphenidate effects on a clinically informative oscillatory signal within the subthalamic nucleus in Parkinson's disease during deep brain stimulation programming. Brain Stimul. 2022; 15(3):747-749.

Bally JF, **Kern DS**, Fearon C, Camargos S, da Silva-Junior FP, Barbosa ER, Ozelius LJ, de Carvalho Aguiar P, Lang AE. DYT-TUBB4A (DYT4 dystonia): clinical anthology of 11 cases and systematized review. *Movement Disorders Clinical Practice*. 2022 Apr 28;9(5):659-675.

Lee T, Fullard M, Rogers T, Ojemann S, Kern D. Patient Preferences for Deep Brain Stimulation Products in Parkinson's Disease: What Really Matters to Them? *Neurology.* May 03, 2022; 98 (18 Supplement).

Jennings D, Huntwork-Rodriguez S, Henry AG, Sasaki JC, Meisner R, Diaz D, Solanoy H, Wang X, Negrou E, Bondar VV, Ghosh R, Maloney MT, Propson NE, Zhu Y, Maciuca R, Harris L, Kay A, LeWitt P, King TA, Kern D, Ellenbogen A, Goodman I, Siderowf A, Aldred J, Omidvar O, Masoud ST, Davis SS, Arguello A, Estrada AA, de Vicente J, Sweeney ZK, Astarita G, Borin MT, Wong BK, Wong H, Nguyen H, Scearce-Levie K, Ho C, Troyer MD. Safety, tolerability, and pharmacodynamics of LRRK2 inhibitor DNL201: from preclinical studies to Parkinson's clinical trials. Sci Transl Med 2022; 14 (648): eabj2658.

Jennings D, Huntwork-Rodriguez S, Henry AG, Sasaki JC, Meisner R, Diaz D, Solanoy H, Wang X, Negrou E, Bondar VV, Ghosh R, **Kern DS**, et al. Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson's disease. Science Translational Medicine. 2022 Jun 8;14(648):eabj2658.

Baumgartner A, Thompson JA, **Kern DS**, Ojemann SG. Novel targets in deep brain stimulation for movement disorders. *Neurosurgical Review*. 2022. Aug;45(4):2593-2613.

Serva SN, Thompson JA, **Kern DS**, Ojemann SG. An update on advanced therapies in movement disorders: from gene therapy to neuromodulation. *Frontiers*. 2022 Sep 23;9:863921.

Tien RN, Tekriwal A, Calame DJ, Platt JP, Baker S, Seeberger LC, **Kern DS**, Person AL, Ojemann SG, Thompson JA, Kramer DR. Deep learning based markerless motion tracking as a clinical tool for movement disorders: utility, feasibility and early experience. Frontiers in Signal Processing. 2022 Sep 29;2:884384.

McQueen RB, Gritz M, **Kern DS**, Bemski JL, Shelton I, Meyer M, Kluger B. Cost and return on investment of a team-based palliative care program for Parkinson's disease. *Neurol Clin Pract*. 2022 Dec;12(6):429-437.

Marsili L, Keeling EG, Maciel R, Contarino MF, Zutt R, Okun MS, Almeida L, Deeb W, **Kern DS**, Macias-Garcia D, Carrillo F, Mir P, Merola A, Espay AJ, Fasano A. Functional Movement Disorders and Deep Brain Stimulation: A Multi-center Study. *Mov Disord Clin Pract*. 2022 Nov 14;10(1):94-100.

Baker S, Tekriwal A, Felsen G, Christensen E, Hirt L, Ojemann SG, Kramer DR, **Kern DS**, Thompson JA. Automatic extraction of upper-limb kinematic activity using deep learning-based markerless tracking during deep brain stimulation implantation for Parkinson's disease: A proof of concept study. *PLoS One*. 2022 Oct 20;17(10):e0275490.

Tekriwal A, Baker S, Christensen E, Petersen-Jones H, Tien RN, Ojemann SG, **Kern DS**, Kramer DR, Felsen G, Thompson JA. Quantifying neuro-motor correlations during awake deep brain stimulation surgery using markerless tracking. *Sci Rep*. 2022 Oct 27;12(1):18120.

Lewis S, Radcliffe E, Ojemann S, Kramer DR, Hirt L, Case M, Holt-Becker AB, Raike R, **Kern DS**, Thompson JA. Pilot Study to Investigate the Use of In-Clinic Sensing to Identify Optimal Stimulation Parameters for Deep Brain Stimulation Therapy in Parkinson's Disease. Neuromodulation: Technology at the Neural Interface. 2023 Feb 14.

Gibbons C, Wang N, Rajan S, **Kern DS**, Palma JA, Kaufmann H, Freeman R. Cutaneous alpha-synuclein signatures differ between patients with multiple system atrophy and Parkinson's disease. *Neurology*. 2023 Apr 11;100(15):e1529-e1539.

Fullard M, Morris M, Dafoe A, Shelton E, Kern D, Matlock D. Improving Shared Decision-Making for Women with Parkinson's Disease. *Neurology.* April 25, 2023; 100 (17 Supplement 2).

Okun M, Foote K, Zesiewicz T, Bezchlibnyk Y, Papanastassiou A, Carlson J, Aldred J, Krishna V, Merola A, Luca C, Jagid J, **Kern DS**, et al. Real-World Outcomes in USA using DBS Systems with Directionality and Multiple Independent Current Control. *Neurology.* April 25, 2023; 100 (17 Supplement 2).

**Kern D**, Dashtipour K, Aldred J, Kimber T, Iansek R, Kukreja P, Bergmann L, Fisseha N, Gupta R, Talapala S, Jeong A. Safety of Foslevodopa/Foscarbidopa During Optimization and Maintenance Treatment: Post Hoc Analysis of a Phase 3 Trial. . *Neurology.* April 25, 2023; 100 (17 Supplement 2).

Radcliffe EM, Baumgartner AJ, **Kern DS**, Al Borno M, Ojemann S, Kramer DR, Thompson JA. Oscillatory beta dynamics inform biomarker-driven treatment optimization for Parkinson's disease. *J Neurophysiol*. 2023 Jun 1;129(6):1492-1504.

Lewis S, Radcliffe E, Ojemann S, Kramer DR, Hirt L, Case M, Holt-Becker AB, Raike R, **Kern DS***, Thompson JA. Pilot Study to Investigate the Use of In-Clinic Sensing to Identify Optimal Stimulation Parameters for Deep Brain Stimulation Therapy in Parkinson's Disease. *Neuromodulation*. 2023 Feb 14:S1094-7159(23)00011-9. *Co-senior author.

Baumgartner A, Hirt L, **Kern D**, Thompson J. Diurnal fluctuations of local field potentials follow sleep-wake behavior in Parkinson's disease. *Research Square*. 2023 Jan 20.

Thompson JA, Hirt L, David-Gerecht P, Fasano A, Kramer DR, Ojemann SG, **Kern DS**. Comparison of Monopolar Review to Fixed Parameter Fractionation in Deep Brain Stimulation. *Mov Disord Clin Pract*. 2023 May 5;10(6):987-991.

Deuel LM, Peterson R, Sillau S, Willis AW, Yu C, **Kern DS**, Fullard M. Gender disparities in deep brain stimulation surgery for Parkinson disease and essential tremor. Deep Brain Stimulation. 2023 June 1: 26-33.

Radcliffe E, Lewis S, Ojemann S, Kramer D, Hirt L, Case M, Holt-Becker A, Raike R, Thompson J, **Kern D**. ID: 209661 Pilot Study Investigating Sensing Utility to Optimize Deep Brain Stimulation Parameters in Parkinson's Disease. Neuromodulation. 2023 Jun 1;26(4):S143.

Frassica M, **Kern DS**, Afshari M, Connolly AT, Wu C, Rowland N, Ramirez-Castaneda J, Ushe M, S alazar C, Mason X. Racial disparities in access to DBS: results of a real-world U.S. claims data analysis. *Front Neurol*. 2023 Aug 1;14:1233684.

**Book chapters**

**Kern DS** and Kumar R. Surgical treatment of Parkinson's disease. In: Samuels MA, and Feske SK, *Office Practice of Neurology*, *2nd edition* 2003.

**Kern DS** and Kumar R. Subthalamic deep brain stimulation. In: Pahwa R, Lyons KE, and Koller W, *Handbook of Parkinson's Disease*, *3rd* edition 2004.

**Kern DS** and Lang AE. Medication-induced acute akathisia. In: Friedman J*, Medication-Induced Movement Disorders*, 2015.

Kahn L, Abosch A, **Kern DS**, Kushida C, Halpern C, and Thompson J. Rapid eye movement sleep behavior disorder: pathological neural circuits and association with Parkinson's disease. In: *Handbook of Sleep Research*. Volume 30: 723-730

Thompson J, **Kern DS**, Ojemann S. Novel targets in deep brain stimulation for movement disorders. In: *Schmidek and Sweet Operative Neurosurgical Techniques 7th Edition* Ed. Quinones-Hinojosa A. Elsevier, 2021.

**Peer-Reviewed Abstracts**

**Kern DS**, Semmler JG, and Enoka RM. Electromyographic activity differs across limbs during normal daily use. *Med Sci Sports Exercise* 132: S28, 2000.

Tracy BL, **Kern DS**, Mehoudar PD, Sehnert SM, Byrnes WC, Enoka RM. Strength training does not improve the steadiness of muscle contractions in the knee extensors of older adults. *Med Sci Sports Exercise*, 33: S5, 2001.

Semmler JG, Kornatz KW, **Kern DS**, and Enoka RM. Motor unit synchronization reduces the steadiness of anisometric contractions by a hand muscle. *Society of Neuroscience* 27, 2001.

Kern DS, McVicker JH, Martin K, and Kumar R. Effective Subthalamic Nucleus (STN) Deep Brain Stimulation (DBS) in Levodopa-unresponsive parkinsonism. *American Academy of Neurology*, 2003.

**Kern DS,** McVicker JH, Martin K, and Kumar R. Sustained long-term benefit and adverse effects of bilateral subthalamic nucleus (STN) deep brain stimulation (DBS) in Parkinson disease (PD). *American Academy of Neurology*, 2003.

McRae C, Murata A, **Kern DS**, McVicker JH, Martin K, and Kumar R. Longitudinal assessment of quality of life among persons receiving deep brain stimulation for the treatment of Parkinson's disease. *Seventeenth Annual Symposium on Etiology, Pathogenesis, and Treatment of Parkinson's Disease*, 2003.

**Kern-DS**, Bjugstad KB, Blanchard BC, Cornelius SK, Maclean KN, Greiner LS, Snyder EY, Sladek Jr. JR. Effects of neural stem cell transplantation on total tau in an aged animal model of Down syndrome, Ts65Dn. *Society for Neuroscience*, 2006.

**Kern-DS**, Bjugstad KB, Blanchard BC, Cornelius SK, Maclean KN, Greiner LS, Snyder EY, Sladek Jr. JR. Effects of neural stem cell transplantation on total tau in an aged animal model of Down's syndrome, Ts65Dn. *Front Range Neuroscience Group*, 2006.

Rachubinski A, Evans J, Johnston K, **Kern DS**, Maclean KN, Bjugstad KB. Effects of neural progenitor cells in a model of Down syndrome. *Society for Neuroscience*, 2007.

**Kern DS**, Blanchard BC, Cornelius SK, Maclean KN, Jiang H, Greiner LS, Snyder EY, Sladek Jr. JR, Bjugstad KB. Short-term neural stem cell treatment in the Ts65Dn mouse model of Down syndrome did not significantly affect total tau in the hippocampus and olfactory bulbs. *American Society for Neural Therapy and Repair*, 2007.

**Kern DS,** Lampe K, Mahoney M, Redmond Jr. DE, Sladek Jr. JR, Bjugstad KB. Biocompatibility of poly(ethylene) glycol (PEG)-based hydrogel in healthy brain tissue. *Society for Neuroscience*, 2007.

**Kern DS**, Maclean KN, Snyder EY, Sladek Jr. JR, Bjugstad KB. Tau positive clusters in the hippocampus are found in greater numbers in the aged Ts65Dn mouse: implanted neural stem cells reduce those numbers. *Society for Neuroscience*, 2008.

Birlea M, Braun C, **Kern DS**, Jones W, Ringel SP, Tyler KL. Improved timeliness of neurology consults in the emergency department. *American Neurological Association*. 2013.

**Kern DS**, Smith EE, Boyer PJ, High WA, Langenberg S, Visanji NP, Hazrati L, Dakheel AA, Marras C, Lang, AE, Kumar R. Methodological approaches for evaluating alpha-synuclein in skin as a potential biomarker in Parkinson's disease. *The International Parkinson and Movement Disorder Society*. 2014.

**Kern DS**, Picillo M, Di Biase L, Munhoz RP, Fasano A. Interleaving deep brain stimulation (DBS) in Parkinson's disease (PD): a retrospective review on rational, management, and outcomes. *American Academy of Neurology*. 2016.

Reddy K, Thaker A, **Kern DS**. Optimized Imaging at 3.0 T of the Rostral Zona Incerta (rZI) for Deep Brain Stimulation (DBS) in Parkinson's Disease (PD). *American Society of Neuroradiology*. 2018.

Thaker A, Reddy K, Thompson JA, David-Gerecht D, Abosch A, **Kern DS**. Optimized Imaging at 3.0 T of the Rostral Zona Incerta (rZI) for Deep Brain Stimulation (DBS) in Parkinson's Disease (PD). *International Congress of Parkinson's Disease and Movement Disorders*. 2018.

Deuel L, Feuerstein J, Berman B, Hoyt B, **Kern DS**. Characteristics of patients with essential tremor evaluated for deep brain stimulation surgery at a tertiary center. *International Congress of Parkinson's Disease and Movement Disorders*. 2019.

**Kern DS**, Kahn L, Ojemann S, Abosch A, Thompson JA. Correlation of local field potentials (LFPs) to electromyography (EMG) of the rostral zona incerta (rZI) and subthalamic nucleus (STN) in Parkinson's Disease (PD). *International Congress of Parkinson's Disease and Movement Disorders*. 2019.

Deuel L, Thompson JA, Kahn L, Barr J, Abosch A, **Kern DS**. Rapid improvement in dystonia after pallidal deep brain stimulation in a patient with myoclonus-dystonia syndrome: A

case report. *International Congress of Parkinson's Disease and Movement Disorders*. 2019.

**Kern DS**, Uy D, Rhoades R, Ojemann S, Abosch A, Thompson JA. *Neuro-anatomical volumetric changes in deep brain stimulation of Parkinson's disease patients*. American Academy of Neurology Annual Meeting. 2020.

Gibbons C, Wang N, Sharika R, **Kern DS**, Jose-Albero P, Horacio K, Roy F. *Cutaneous alpha-synuclein deposition across synucleinopathies*. American Academy of Neurology Annual Meeting. 2020.

Petersen-Jones H, **Kern DS**, Kahn L, Ojemann S, Abosch A, Thompson JA. *Correlation of local field potentials to electromyography of the rostral zona incerta and subthalamic nucleus in Parkinson's disease*. American Society for Stereotactic and Functional Neurosurgery. 2020.

Lewis S, Hirt L, Case M, Pulliam C, Eubanks, J, Goetz S, Raike RS, Ojemann S, Kramer D, **Kern D**, Thompson JA. *Acute localization of maximum beta power within the subthalamic nucleus using clinic local field potential recordings reveals minimal variability in the peak frequency*. Society for Neuroscience. 2021.

Baker S, Ojemann S, Kramer D, **Kern DS**, Thompson JA. *Automatic extraction of kinematic motifs captured with markerless tracking during deep brain stimulation implantation*. Society for Neuroscience. 2021.

Baumgartner AJ, Hirt L, **Kern DS**, Thompson JA. *Naturalistic sleep in Parkinson's disease assessed by actigraphy and direct recordings of the subthalamic nucleus*. Society for Neuroscience. 2021.

Isaacson SH, Di Lorenzo G, Facheris MF, Fung V, Henriksen T, Ikenaka K, Jia J, **Kern DS,** Kukreja P, Garcia DS, Spiegel A, Zhang Z, Bergmann L, Carroll C. *Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Results by Age, Disease Duration, and Baseline "Off" Time*. EAN 2022.

Lewis S, Hirt L, Case, M, Holt-Becker A, Raike R, Ojemann S, Kramer D, **Kern DS**, Thompson JA. Pilot study to investigate the use of in-clinic sensing to identify optimal stimulation parameters for deep brain stimulation therapy in Parkinson's disease. *International Congress of Parkinson's Disease and Movement Disorders*. 2022.

Thompson JA, Ojemann SG, Kramer DR, Hirt L, Radcliffe E, Case M, Zarns C, Holt-Becker A, Raike R, Baumgartner AJ, **Kern DS**. Pilot study to investigate the use of monopolar sensing to improve the efficiency of DBS programming in Parkinson's disease. Poster presented at: International Congress of Parkinson's Disease and Movement Disorders. 2023 August 29; Copenhagen, DK.

Thompson JA, Hirt L, **Kern DS**, Baumgartner AJ. Characterization of at-home sleep macrostructure in Parkinson disease using a wearable sleep monitoring device. Poster presented at: International Congress of Parkinson's Disease and Movement Disorders. 2023 August 28; Copenhagen, DK.